MedPath
HSA Approval

Pembrolizumab Solution for Infusion 25mg/mL

SIN16677P

Pembrolizumab Solution for Infusion 25mg/mL

Pembrolizumab Solution for Infusion 25mg/mL

January 13, 2023

MSD PHARMA (SINGAPORE) PTE. LTD.

MSD PHARMA (SINGAPORE) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMSD PHARMA (SINGAPORE) PTE. LTD.
Licence HolderMSD PHARMA (SINGAPORE) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01XC18

xl 01 xc 18

Manufacturer Information

MSD PHARMA (SINGAPORE) PTE. LTD.

MSD International GmbH T/A MSD Ireland (Carlow)

Active Ingredients

Pembrolizumab

25.0mg/mL

Pembrolizumab

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.